Sobi invests $915m in Dova and its hematology portfolio 03-Oct-2019 By Ben Hargreaves Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.